Sponsors (7)
The bill reduces direct-to-consumer drug advertising and associated misleading promotion (lowering some patient confusion and marketing-driven costs) but also limits a consumer information channel, may slow uptake of beneficial medicines, and could shift promotional pressure and costs to other actors.
Patients with chronic conditions will be exposed to fewer direct-to-consumer prescription drug ads, reducing their exposure to potentially misleading or confusing promotional claims.
Hospitals, health systems, and clinicians will face less pressure from patient requests for heavily marketed brand drugs, easing burdens on clinical decision-making and workflow.
Patients and taxpayers could see lower marketing-driven drug spending, which may slow price inflation tied to heavy consumer promotion.
Patients with chronic conditions may have less awareness of new treatments or new indications, slowing uptake of clinically beneficial drugs and delaying potential health benefits.
Drug manufacturers, hospitals, and patients will lose a major channel to convey information about drug benefits, side effects, and availability, reducing one source of consumer-facing safety and access information.
Drug makers may shift promotional efforts toward clinicians or alternative marketing channels, potentially increasing industry spending in other areas and moving pressure onto providers.
Based on analysis of 2 sections of legislative text.
Bans direct-to-consumer advertising for FDA-approved prescription drugs and licensed biologics across TV, radio, print, digital, and social media, effective 30 days after enactment.
Official title: Ban drug manufacturers from using direct-to-consumer advertising, including social media, to promote their products.
Introduced June 12, 2025 by Bernard Sanders · Last progress June 12, 2025
Prohibits direct-to-consumer (DTC) advertising for prescription drugs and biologics that are approved or licensed by the FDA or HHS, and that have been the subject of DTC promotion within the prior 30 days. The ban covers promotional communications directed at consumers across TV, radio, print, digital platforms, and social media, becomes effective 30 days after enactment, and applies to drugs and biologics approved or licensed at any time.